type AL amyloidosis
Conditions
Interventions
Group 1:the combination regimen of bortezomib +thalidomide + dexamethasone (VTD)
Group 2:the combination regimen of bortezomib + cyclophosphamide + dexamethasone (VCD)
Sponsors
Guangdong General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: (1) signed a written informed consent; (2) aged between 18 and 75 years male or female; (3) primary disease accumulated by the system or organ (kidney, heart, liver, skin biopsy) clear AL amyloidosis, investigation and other secondary factors; (4) bone marrow or blood / urine fixed electrophoresis tips monoclonal plasmacytosis.
Exclusion criteria
Exclusion criteria: (1) biopsy for non AL amyloidosis; (2) plasma cells of multiple myeloma or other hematologic malignancies; (3) related diseases complicated with glaucoma, severe osteoporosis and peptic ulcer hemorrhage / history, mental disorders, Cushing syndrome and other hormone taboo; (4) combined infection, hepatitis, tuberculosis or other immunosuppressive taboo of the disease; (5) pregnant or lactating women; (6) there is a history of allergies or nearly 4 weeks of acute or chronic allergy to drugs used in clinical trials; (10) the life of less than expected 1 years; (11) the researchers estimate the compliance of patients is not suitable to participate in this study; (12) the past or present a history of cancer, the risk of tumor recurrence or metastasis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| complete remission;Organ response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| very good partial remission;partial remission;Survival Data Analysis;Overall survival rate;Progression free survival; | — |
Countries
China
Contacts
Public ContactWang Wenjian
Guangdong General Hospital
Outcome results
None listed